Patents Examined by Erinne R Dabkowski
  • Patent number: 10844094
    Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) fconstituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 24, 2020
    Inventors: Arne Skerra, Uli Binder, Martin Schlapschy
  • Patent number: 10844093
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: November 24, 2020
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Patent number: 10844090
    Abstract: Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 24, 2020
    Inventors: Toni Kline, Qun Yin, Krishna Bajjuri
  • Patent number: 10835579
    Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 17, 2020
    Inventor: Alex Sinclair
  • Patent number: 10829530
    Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: November 10, 2020
    Inventor: Varda Shoshan-Barmatz
  • Patent number: 10821136
    Abstract: The present invention provides a bone formation promoter having high biological safety and capable of promoting bone formation. The bone formation promoter of the present invention includes a self-assembling peptide capable of forming a ?-sheet structure in an aqueous solution having a neutral pH; and a bone chip. A sum of charges of amino acid residues constituting the self-assembling peptide at pH 7.0 is unequal to 0.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: November 3, 2020
    Inventors: Kei Ando, Naoki Ishiguro, Shiro Imagama, Zenya Ito, Yasuhiro Yokoyama, Hidenori Yokoi, Yusuke Nagai
  • Patent number: 10822388
    Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: November 3, 2020
    Assignee: University Health Network
    Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
  • Patent number: 10806798
    Abstract: The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: October 20, 2020
    Assignee: Shanghai Lumosa Therapeutics Co., Ltd.
    Inventors: Shiqi Peng, Ming Zhao, Xueyun Jiang
  • Patent number: 10806775
    Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: October 20, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Patent number: 10793598
    Abstract: Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 6, 2020
    Assignee: Rush University Medical Center
    Inventors: Sanda Predescu, Dan Predescu
  • Patent number: 10780143
    Abstract: Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (PRR) antagonist. In some instances the PRR antagonist is a polypeptide. The PRR antagonist can be a polypeptide having at least 70% identity to the amino acid sequence set forth in SEQ ID NO:2. Also disclosed are methods of decreasing proteinuria and methods of promoting wound healing by administering a PRR antagonist.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 22, 2020
    Inventors: Yumei Feng Earley, Tianxin Yang
  • Patent number: 10772966
    Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 15, 2020
    Assignee: OPHIDION INC.
    Inventor: Andreas Walz
  • Patent number: 10775393
    Abstract: Disclosed is a reagent for prothrombin time measurement, wherein the reagent contains a liposome composition containing a first liposome having a phospholipid layer, a second liposome having a phospholipid layer of a different composition from that of the first liposome, and tissue factor, wherein the tissue factor is associated with the phospholipid layer of at least one of the first liposome and the second liposome; the first liposome contains a phosphatidylcholine compound, a phosphatidylethanolamine compound, and a phosphatidylserine compound; and the second liposome contains at least one phospholipid selected from the group consisting of a phosphatidylcholine compound and a phosphatidylethanolamine compound.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: September 15, 2020
    Inventors: Yusuke Tanaka, Takahiko Bando, Kiyoko Kohama, Haruki Yamaguchi
  • Patent number: 10774118
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 15, 2020
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 10774131
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: September 15, 2020
    Inventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
  • Patent number: 10772927
    Abstract: The present invention relates to the use of a casein hydrolysate as an antiviral agent for the treatment of opportunistic virus infections, especially herpesvirus and human papillomavirus. This casein hydrolysate has an application in both the therapeutic treatment of established symptoms and the prevention of the infection or the reactivation of a latent infection by an opportunistic virus. The casein hydrolysate of the present invention is effective for the prevention of opportunistic virus infections in individuals with weakened immune system.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: September 15, 2020
    Assignee: NTD Labs, S.L.
    Inventors: Pere Adell Winkler, Guillermo Lopez Zarco
  • Patent number: 10745458
    Abstract: An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analogue or single-chain insulin analogue contains a B domain containing a cyclohexanylalanine substitution at position B24 and optionally contains additional amino-acid substitutions at positions A8, B28, and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Case Western Reserve University
    Inventor: Michael A. Weiss
  • Patent number: 10722608
    Abstract: The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: July 28, 2020
    Assignee: University of Rochester
    Inventor: Majed A. Refaai
  • Patent number: 10709655
    Abstract: The present invention provides a composition that comprises at least one peptide with a sequence length of 6-12 amino acids, where 2-5 of those amino acids are cysteines for the treatment of the hair, including animal and human hair, without the use of chemicals harmful to the hair fiber and consumer health and uses of said compositions in shampoo, lotion, serum, cream, conditioner, foam, elixir, oil, aerosol or mask.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: July 14, 2020
    Inventors: Artur Manuel Cavaco Paulo, Celia Freitas Da Cruz, Margarida Maria Macedo Francesko Fernandes
  • Patent number: 10696721
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao